Contemporary challenges in the diagnosis and management of chronic inflammatory demyelinating polyneuropathy

References

• Rajabally YA, Simpson BS, Beri S, et al. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve. 2009;39(4):432–438.
   PubMed Web of Science ®Google Scholar
• Broers MC, Bunschoten C, Nieboer D, et al. Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Neuroepidemiology. 2019;52(3–4):161–172.
   PubMed Web of Science ®Google Scholar
• Van den Bergh PY, Hadden RD, Bouche P, et al. European federation of neurological societies/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the european federation of neurological societies and the peripheral nerve society - first revision. Eur J Neurol. 2010;17(3):356–363.
   PubMed Web of Science ®Google Scholar
• Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European academy of neurology/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision. Eur J Neurol. 2021;28(11):3556–3583.
   PubMed Web of Science ®Google Scholar
• Hughes RA, Bouche P, Cornblath DR, et al. European federation of neurological societies/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European federation of neurological societies and the peripheral nerve society. Eur J Neurol. 2006;13(4):326–332.
   PubMed Web of Science ®Google Scholar
• Mathey EK, Park SB, Hughes RA, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry. 2015;86(9):973–985.
   PubMed Web of Science ®Google Scholar
• Koike H, Nishi R, Ikeda S, et al. Ultrastructural mechanisms of macrophage-induced demyelination in CIDP. Neurology. 2018;91(23):1051–1060.
   PubMed Web of Science ®Google Scholar
• Koike H, Kadoya M, Kaida KI, et al. Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies. J Neurol Neurosurg Psychiatry. 2017;88(6):465–473.
   PubMed Web of Science ®Google Scholar
• Van den Bergh PY, Rajabally YA. Chronic inflammatory demyelinating polyradiculoneuropathy. Presse Med. (Paris, France: 1983). 2013;42(6 Pt 2):e203–15.
   PubMedGoogle Scholar
• Allen JA, Lewis RA. CIDP diagnostic pitfalls and perception of treatment benefit. Neurology. 2015;85(6):498–504.
   PubMed Web of Science ®Google Scholar
• Chaudhary UJ, Rajabally YA. Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy. J Neurol. 2021;268(4):1366–1373.
   PubMed Web of Science ®Google Scholar
• Broers MC, Bunschoten C, Drenthen J, et al. Misdiagnosis and diagnostic pitfalls of chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2021;28(6):2065–2073.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Peric S, Cobeljic M, et al. Chronic inflammatory demyelinating polyneuropathy associated with diabetes: a European multicentre comparative reappraisal. J Neurol Neurosurg Psychiatry. 2020;91(10):1100–1104.
   PubMed Web of Science ®Google Scholar
• Doneddu PE, Cocito D, Manganelli F, et al. Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy. J Neurol Neurosurg Psychiatry. 2020;91(10):1092–1099.
   PubMed Web of Science ®Google Scholar
• Ruts L, Drenthen J, Jacobs BC, et al. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology. 2010;74(21):1680–1686.
   PubMed Web of Science ®Google Scholar
• Tackenberg B, Lünemann JD, Steinbrecher A, et al. Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy. Neurology. 2007;68(19):1622–1629.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Adams D, Latour P, et al. Hereditary and inflammatory neuropathies: a review of reported associations, mimics and misdiagnoses. J Neurol Neurosurg Psychiatry. 2016;87(10):1051–1060.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Nicolas G, Pieret F, et al. Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European study. J Neurol Neurosurg Psychiatry. 2009;80(12):1364–1368.
   PubMed Web of Science ®Google Scholar
• Breiner A, Brannagan TH. Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2014;50(1):40–46. 3rd.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Jacob S, Hbahbih M. Optimizing the use of electrophysiology in the diagnosis of chronic inflammatory demyelinating polyneuropathy: a study of 20 cases. J Peripher Nerv Syst: JPNS. 2005;10(3):282–292.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Narasimhan M. Distribution, clinical correlates and significance of axonal loss and demyelination in chronic inflammatory demyelinating polyneuropathy. Eur J Neurol. 2011;18(2):293–299.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Jacob S. Proximal nerve conduction studies in chronic inflammatory demyelinating polyneuropathy. Clin Neurophysiol. 2006;117(9):2079–2084.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Lagarde J, Cassereau J, et al. A European multicentre reappraisal of distal compound muscle action potential duration in chronic inflammatory demyelinating polyneuropathy. Eur J Neurol. 2012;19(4):638–642.
   PubMed Web of Science ®Google Scholar
• Mitsuma S, Van den Bergh P, Rajabally YA, et al. Effects of low frequency filtering on distal compound muscle action potential duration for diagnosis of CIDP: a Japanese-European multicenter prospective study. Clin Neurophysiol. 2015;126(9):1805–1810.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Varanasi S. Practical electrodiagnostic value of F-wave studies in chronic inflammatory demyelinating polyneuropathy. Clin Neurophysiol. 2013;124(1):171–175.
   PubMed Web of Science ®Google Scholar
• Bragg JA, Benatar MG. Sensory nerve conduction slowing is a specific marker for CIDP. Muscle Nerve. 2008;38(6):1599–1603.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Samarasekera S. Electrophysiological sensory demyelination in typical chronic inflammatory demyelinating polyneuropathy. Eur J Neurol. 2010;17(7):939–944.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Narasimhan M. The value of sensory electrophysiology in chronic inflammatory demyelinating polyneuropathy. Clin Neurophysiol. 2007;118(9):1999–2004.
   PubMed Web of Science ®Google Scholar
• Tamura N, Kuwabara S, Misawa S, et al. Superficial radial sensory nerve potentials in immune-mediated and diabetic neuropathies. Clin Neurophysiol. 2005;116(10):2330–2333.
   PubMed Web of Science ®Google Scholar
• Wong AH, Umapathi T, Nishimoto Y, et al. Cytoalbuminologic dissociation in Asian patients with Guillain-Barré and Miller Fisher syndromes. J Peripher Nerv Syst: JPNS. 2015;20(1):47–51.
   PubMed Web of Science ®Google Scholar
• Liberatore G, Manganelli F, Cocito D, et al. Relevance of diagnostic investigations in chronic inflammatory demyelinating poliradiculoneuropathy: data from the italian cidp database. J Peripher Nerv Syst: JPNS. 2020;25(2):152–161.
   Web of Science ®Google Scholar
• Rajabally YA, Chavada G. Lewis-sumner syndrome of pure upper-limb onset: diagnostic, prognostic, and therapeutic features. Muscle Nerve. 2009;39(2):206–220.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Stettner M, Kieseier BC, et al. CIDP and other inflammatory neuropathies in diabetes - diagnosis and management. Nat Rev Neurol. 2017;13(10):599–611.
   PubMed Web of Science ®Google Scholar
• Bourque PR, Brooks J, McCudden CR, et al. Age matters: impact of data-driven CSF protein upper reference limits in Guillain-Barré syndrome. Neurol Neuroimmunol Neuroinflamm. 2019;6(4):e576.
   PubMed Web of Science ®Google Scholar
• Hegen H, Ladstätter F, Bsteh G, et al. Cerebrospinal fluid protein in Guillain-Barré syndrome: need for age-dependent interpretation. Eur J Neurol. 2021;28(3):965–973.
   PubMed Web of Science ®Google Scholar
• Breiner A, Bourque PR, Allen JA. Updated cerebrospinal fluid total protein reference values improve chronic inflammatory demyelinating polyneuropathy diagnosis. Muscle Nerve. 2019;60(2):180–183.
   PubMed Web of Science ®Google Scholar
• Goedee HS, Jongbloed BA, van Asseldonk JH, et al. A comparative study of brachial plexus sonography and magnetic resonance imaging in chronic inflammatory demyelinating neuropathy and multifocal motor neuropathy. Eur J Neurol. 2017;24(10):1307–1313.
   PubMed Web of Science ®Google Scholar
• Goedee HS, van der Pol WL, Hendrikse J, et al. Nerve ultrasound and magnetic resonance imaging in the diagnosis of neuropathy. Curr Opin Neurol. 2018;31(5):526–533.
   PubMed Web of Science ®Google Scholar
• Shibuya K, Sugiyama A, Ito S, et al. Reconstruction magnetic resonance neurography in chronic inflammatory demyelinating polyneuropathy. Ann Neurol. 2015;77(2):333–337.
   PubMed Web of Science ®Google Scholar
• van Rosmalen MHJ, Goedee HS, van der Gijp A, et al. Quantitative assessment of brachial plexus MRI for the diagnosis of chronic inflammatory neuropathies. J Neurol. 2021;268(3):978–988.
   PubMed Web of Science ®Google Scholar
• Massie R, Mauermann ML, Staff NP, et al. Diabetic cervical radiculoplexus neuropathy: a distinct syndrome expanding the spectrum of diabetic radiculoplexus neuropathies. Brain. 2012;135(Pt 10):3074–3088.
   PubMedGoogle Scholar
• Koide K, Sugiyama A, Yokota H, et al. Nerve hypertrophy and altered diffusion in anti-myelin-associated glycoprotein neuropathy detected by brachial plexus magnetic resonance neurography. Eur Neurol. 2021;1–9. https://doi.org/10.1159/000519128
   Google Scholar
• Ziff OJ, Hoskote C, Keddie S, et al. Frequent central nervous system, pachymeningeal and plexus MRI changes in POEMS syndrome. J Neurol. 2019;266(5):1067–1072.
   PubMed Web of Science ®Google Scholar
• Chhabra A, Carrino JA, Farahani SJ, et al. Whole-body MR neurography: prospective feasibility study in polyneuropathy and Charcot-Marie-Tooth disease. J Magn Reson Imaging. 2016;44(6):1513–1521.
   PubMed Web of Science ®Google Scholar
• Oudeman J, Eftimov F, Strijkers GJ, et al. Diagnostic accuracy of MRI and ultrasound in chronic immune-mediated neuropathies. Neurology. 2020;94(1):e62–e74.
   PubMed Web of Science ®Google Scholar
• Telleman JA, Herraets IJT, Goedee HS, et al. Nerve ultrasound: a reproducible diagnostic tool in peripheral neuropathy. Neurology. 2018. https://doi.org/10.1212/WNL.0000000000006856.
   Google Scholar
• Herraets IJT, Goedee HS, Telleman JA, et al. Nerve ultrasound improves detection of treatment-responsive chronic inflammatory neuropathies. Neurology. 2020;94(14):e1470–e9.
   PubMed Web of Science ®Google Scholar
• Herraets IJT, Goedee HS, Telleman JA, et al. Nerve ultrasound for diagnosing chronic inflammatory neuropathy: a multicenter validation study. Neurology. 2020;95(12):e1745–e53.
   PubMed Web of Science ®Google Scholar
• Goedee HS, Herraets IJT, Visser LH, et al. Nerve ultrasound can identify treatment-responsive chronic neuropathies without electrodiagnostic features of demyelination. Muscle Nerve. 2019;60(4):415–419.
   PubMed Web of Science ®Google Scholar
• Ding Q, Li J, Guan Y, et al. Nerve ultrasound studies in POEMS syndrome. Muscle Nerve. 2021;63(5):758–764.
   PubMed Web of Science ®Google Scholar
• Lucchetta M, Padua L, Granata G, et al. Nerve ultrasound findings in neuropathy associated with anti-myelin-associated glycoprotein antibodies. Eur J Neurol. 2015;22(1):193–202.
   PubMed Web of Science ®Google Scholar
• Grimm A, Rasenack M, Athanasopoulou IM, et al. The modified ultrasound pattern sum score mUPSS as additional diagnostic tool for genetically distinct hereditary neuropathies. J Neurol. 2016;263(2):221–230.
   PubMed Web of Science ®Google Scholar
• Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc subcommittee of the American academy of neurology AIDS Task Force. Neurology. 1991;41(5):617–618.
   PubMedGoogle Scholar
• Molenaar DS, Vermeulen M, de Haan R. Diagnostic value of sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 1998;64(1):84–89.
   PubMed Web of Science ®Google Scholar
• Sommer CL, Brandner S, Dyck PJ, et al. Peripheral nerve society guideline on processing and evaluation of nerve biopsies. J Peripher Nerv Syst: JPNS. 2010;15(3):164–175.
   PubMed Web of Science ®Google Scholar
• Vallat JM, Tabaraud F, Magy L, et al. Diagnostic value of nerve biopsy for atypical chronic inflammatory demyelinating polyneuropathy: evaluation of eight cases. Muscle Nerve. 2003;27(4):478–485.
   PubMed Web of Science ®Google Scholar
• Pascual-Goñi E, Martín-Aguilar L, Lleixà C, et al. Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy. Sci Rep. 2019;9(1):6155.
   PubMedGoogle Scholar
• Rajabally YA. Neuropathy and paraproteins: review of a complex association. Eur J Neurol. 2011;18(11):1291–1298.
   PubMed Web of Science ®Google Scholar
• Attarian S, Boucraut J, Hubert AM, et al. Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies: response to IVIg therapy. J Neurol Neurosurg Psychiatry. 2010;81(1):61–64.
   PubMed Web of Science ®Google Scholar
• Sahi N, Ghasemi M, Rajabally YA. Autoantibodies in the diagnostic work-up of neuropathy: clinically useful or purely academic? Br J Hosp Med (Lond). 2020;81(7):1–9.
   PubMed Web of Science ®Google Scholar
• Querol L, Devaux J, Rojas-Garcia R, et al. Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications. Nat Rev Neurol. 2017;13(9):533–547.
   PubMed Web of Science ®Google Scholar
• Delmont E, Brodovitch A, Kouton L, et al. Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera. J Neurol. 2020;267(12):3664–3672.
   PubMed Web of Science ®Google Scholar
• Lunn MP, Ellis L, Hadden RD, et al. A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies. J Peripher Nerv Syst: JPNS. 2016;21(1):33–37.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Afzal S. Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy. J Neurol. 2019;266(2):461–467.
   PubMed Web of Science ®Google Scholar
• Stino AM, Naddaf E, Dyck PJ, et al. Chronic inflammatory demyelinating polyradiculoneuropathy-Diagnostic pitfalls and treatment approach. Muscle Nerve. 2021;63(2):157–169.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Fatehi F. Outcome measures for chronic inflammatory demyelinating polyneuropathy in research: relevance and applicability to clinical practice. Neurodegener Dis Manag. 2019;9(5):259–266.
   PubMed Web of Science ®Google Scholar
• Vanhoutte EK, Faber CG, van Nes SI, et al. Modifying the medical research council grading system through Rasch analyses. Brain. 2012;135(Pt 5):1639–1649.
   PubMedGoogle Scholar
• Rajabally YA, Ghasemi M. Comparative value and determinants of suitability of outcome measures in treated chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2020;61(2):182–186.
   PubMed Web of Science ®Google Scholar
• Oaklander AL, Lunn MP, Hughes RA, et al. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev. 2017;1(1):Cd010369.
   PubMedGoogle Scholar
• Eftimov F, Winer JB, Vermeulen M, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2013;12:Cd001797. https://doi.org/10.1002/14651858.CD001797.pub3
   PubMed Web of Science ®Google Scholar
• van Schaik IN, Eftimov F, van Doorn PA, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(3):245–253.
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Cocito D, Jann S, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol. 2012;11(6):493–502.
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Cocito D, Jann S, et al. Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP. J Neurol Neurosurg Psychiatry. 2015;86(7):729–34.*. of importance: comparative anaslysis of immunoglobulins versus steroids with regards to relapse rate and time in CIDP.
   PubMed Web of Science ®Google Scholar
• Bus SRM, Zambreanu L, Abbas A, et al. Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC). Trials. 2021;22(1):155.
   PubMed Web of Science ®Google Scholar
• Debs R, Reach P, Cret C, et al. A new treatment regimen with high-dose and fractioned immunoglobulin in a special subgroup of severe and dependent CIDP patients. Int J Neurosci. 2017;127(10):864–872.
   PubMed Web of Science ®Google Scholar
• Rajabally YA. Unconventional treatments for chronic inflammatory demyelinating polyneuropathy. Neurodegener Dis Manag. 2017;7(5):331–342.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Seow H, Wilson P. Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst: JPNS. 2006;11(4):325–329.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Wong SL, Kearney DA. Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens? J Neurol. 2013;260(8):2052–2056.
   PubMed Web of Science ®Google Scholar
• Kapoor M, Compton L, Rossor A, et al. An approach to assessing immunoglobulin dependence in chronic inflammatory demyelinating inflammatory polyneuropathy. J Peripher Nerv Syst: JPNS. 2021;26(4):461–468.
   PubMed Web of Science ®Google Scholar
• Fatehi F, Okhovat AA, Panahi A, et al. Retrospective analysis of response to rituximab in chronic inflammatory demyelinating polyneuropathy refractory to first-line therapy. J Peripher Nerv Syst: JPNS. 2021;26(4):469–474.
   PubMed Web of Science ®Google Scholar
• Léger JM, Viala K, Nicolas G, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology. 2013;80(24):2217–2225.
   PubMed Web of Science ®Google Scholar
• Good JL, Chehrenama M, Mayer RF, et al. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology. 1998;51(6):1735–1738.
   PubMed Web of Science ®Google Scholar
• Allen JA, Pasnoor M, Dimachkie MM, et al. Quantifying treatment-related fluctuations in CIDP: results of the GRIPPER study. Neurology. 2021;96(14):e1876–e86.
   PubMed Web of Science ®Google Scholar
• White D, Englezou C, Rajabally YA. Patient perceptions of outcome measures in chronic inflammatory demyelinating polyneuropathy: a study of the Inflammatory Rasch-built overall disability scale. Eur J Neurol. 2021;28(8):2596–2602.
   PubMed Web of Science ®Google Scholar
• Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50(2):195–201.
   PubMed Web of Science ®Google Scholar
• Graham RC, Hughes RA. A modified peripheral neuropathy scale: the overall neuropathy limitations scale. J Neurol Neurosurg Psychiatry. 2006;77(8):973–976.
   PubMed Web of Science ®Google Scholar
• van Nes SI, Vanhoutte EK, van Doorn PA, et al. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology. 2011;76(4):337–345.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Narasimhan M. Jamar hand-held grip dynamometry in chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2013;325(1–2):36–38.
   PubMed Web of Science ®Google Scholar
• Vanhoutte EK, Latov N, Deng C, et al. Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG–the ICE study. Eur J Neurol. 2013;20(5):748–755.
   PubMed Web of Science ®Google Scholar
• Markvardsen LH, Debost JC, Harbo T, et al. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2013;20(5):836–842.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Afzal S, Ghasemi M. Minimal important differences and self-identifying treatment response in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2021;64(1):37–42.
   PubMedGoogle Scholar
• Spina E, Topa A, Iodice R, et al. Six-minute walk test is reliable and sensitive in detecting response to therapy in CIDP. J Neurol. 2019;266(4):860–865.
   PubMed Web of Science ®Google Scholar
• Bril V, Banach M, Dalakas MC, et al. Electrophysiologic correlations with clinical outcomes in CIDP. Muscle Nerve. 2010;42(4):492–497.
   PubMed Web of Science ®Google Scholar
• Bril V, Hartung HP, Lawo JP, et al. Electrophysiological testing in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin: the Polyneuropathy And Treatment with Hizentra (PATH) study. Clin Neurophysiol. 2021;132(1):226–231.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Goedee HS. Electrophysiology in CIDP: should we use it beyond diagnosis? Clin Neurophysiol. 2021;132(1):204–206.
   PubMed Web of Science ®Google Scholar
• Lawley A, Seri S, Rajabally YA. Motor unit number index (MUNIX) in chronic inflammatory demyelinating polyneuropathy: a potential role in monitoring response to intravenous immunoglobulins. Clin Neurophysiol. 2019;130(10):1743–1749.
   PubMed Web of Science ®Google Scholar
• Okhovat AA, Advani S, and Ziaadini B, et al. The value of MUNIX as an objective electrophysiological biomarker of disease progression in CIDP. Muscle Nerve. In Press, 2022.
   PubMed Web of Science ®Google Scholar
• Michaelides A, Hadden RDM, Sarrigiannis PG, et al. Pain in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: a systematic review and meta-analysis. Pain Ther. 2019;8(2):177–185.
   PubMed Web of Science ®Google Scholar
• Lawley A, Abbas A, Seri S, et al. Clinical correlates of fatigue in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2020;62(2):226–232.
   PubMed Web of Science ®Google Scholar
• Cao Y, Menon P, Ching-Fen Chang F, et al. Postural tremor and chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2017;55(3):338–343.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Shah RS. Restless legs syndrome in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2010;42(2):252–256.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Seri S, Cavanna AE. Neuropsychiatric manifestations in inflammatory neuropathies: a systematic review. Muscle Nerve. 2016;54(1):1–8.
   PubMed Web of Science ®Google Scholar
• Uncini A, Sabatelli M, Mignogna T, et al. Chronic progressive steroid responsive axonal polyneuropathy: a CIDP variant or a primary axonal disorder? Muscle Nerve. 1996;19(3):365–371.
   PubMed Web of Science ®Google Scholar
• Iijima M, Yamamoto M, Hirayama M, et al. Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP. Neurology. 2005;64(8):1471–1475.
   PubMed Web of Science ®Google Scholar
• Rajabally YA. The “chronic immune polyradiculopathies”: diverse but maybe just CIDP after all. Muscle Nerve. 2021;63(1):7–9.
   PubMed Web of Science ®Google Scholar
• Kouton L, Boucraut J, Devaux J, et al. Electrophysiological features of chronic inflammatory demyelinating polyradiculoneuropathy associated with IgG4 antibodies targeting neurofascin 155 or contactin 1 glycoproteins. Clin Neurophysiol. 2020;131(4):921–927.
   PubMed Web of Science ®Google Scholar
• Doneddu PE, Cocito D, Manganelli F, et al. Atypical CIDP: diagnostic criteria, progression and treatment response. data from the Italian CIDP database. J Neurol Neurosurg Psychiatry. 2019;90(2):125–132.
   PubMed Web of Science ®Google Scholar
• Sinnreich M, Klein CJ, Daube JR, et al. Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia. Neurology. 2004;63(9):1662–1669.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, and Goedee HS. Dysimmune neuropathies. In: Rajabally YA, editor. Chronic inflammatory demyelinating polyneuropathy. London (UK): Elsevier; 2020:31–81.
   Google Scholar